



Australian Government
Department of Health and Aged Care
 Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	342333	Eagle Joint Ease
ARTG entry for	Medicine Listed	
Sponsor	Integria Healthcare Australia Pty Ltd	
Postal Address	PO Box 4854, EIGHT MILE PLAINS, QLD, 4113 Australia	
ARTG Start Date	26/08/2020	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Eagle Joint Ease

Product Type	Single Medicine Product	Effective Date	5/11/2021
--------------	-------------------------	----------------	-----------

Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Helps reduce/decrease free radical damage to body cells
- Maintain/support general health and wellbeing
- Helps decrease/reduce/relieve cartilage loss/wear/tear/damage
- Decrease/reduce/relieve mild joint aches and pains in elderly individuals
- Decrease/reduce/relieve mild joint aches and pains
- Decrease/reduce/relieve mild rheumatic aches and pains
- Decrease/reduce/relieve mild rheumatic aches and pains in elderly individuals
- Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis in elderly individuals
- Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis
- Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis
 - Linked indication - Decrease/reduce/relieve mild joint inflammation/swelling
 - Linked indication - Decrease/reduce/relieve mild rheumatic aches and pains
 - Linked indication - Decrease/reduce/relieve mild joint aches and pains
 - Linked indication - Decrease/reduce/relieve mild joint pain/soreness
 - Linked indication - Decrease/reduce/relieve mild joint stiffness
- Helps maintain/supports healthy joint cartilage growth/development/production
- Helps maintain/support joint cartilage health
- Helps enhance/promote healthy joint function in elderly individuals
- Helps enhance/promote healthy joint function
- Helps enhance/promote joint health in elderly individuals
- Helps enhance/promote joint health
- Maintain/support joint health
- Decrease/reduce/relieve mild joint inflammation/swelling
- Decrease/reduce/relieve mild joint inflammation/swelling in elderly individuals
- Maintain/support joint mobility/flexibility in elderly individuals
- Maintain/support joint mobility/flexibility
- Helps enhance/improve/promote joint mobility in elderly individuals

Public Summary



Australian Government
Department of Health and Aged Care
 Therapeutic Goods Administration

Helps enhance/improve/promote joint mobility
 Decrease/reduce/relieve mild joint pain/soreness in elderly individuals
 Decrease/reduce/relieve mild joint pain/soreness
 Decrease/reduce/relieve mild joint stiffness in elderly individuals
 Decrease/reduce/relieve mild joint stiffness

Indication Requirements

Product presentation must not imply or refer to any form of arthritis or osteoarthritis unless qualified as mild.
 Label statement: If symptoms persist, talk to your health professional.
 Product presentation must only refer to mild joint symptoms.
 Product presentation must only refer to mild rheumatic aches/pains.
 Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.
 Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Contains crustacea OR Contains crustacean products.
 Derived from seafood.
 Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.
 For practitioner dispensing only.
 Contains potassium. If you have kidney disease or are taking heart or blood pressure medicines, consult your doctor or pharmacist before use. Keep out of reach of children.
 If symptoms persist, seek the advice of a healthcare professional.

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral

Visual Identification

Active Ingredients

Boswellia serrata gum Extract dry concentrate	57.14 mg
Equivalent: Boswellia serrata (Dry)	400 mg
colecalfiferol	.0025 mg
Curcuma longa rhizome Extract dry concentrate	4 mg
Equivalent: Curcuma longa (Dry)	100 mg
glucosamine sulfate potassium chloride	663 mg
Equivalent: glucosamine sulfate	500 mg
Equivalent: potassium chloride	163 mg
lecithin	100 mg
magnesium orotate dihydrate	103.58 mg
Equivalent: magnesium	6.65 mg
manganese amino acid chelate	25 mg
Equivalent: manganese	5 mg
nicotinamide	200 mg
Silybum marianum seed Extract dry concentrate	5 mg

Public Summary



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Equivalent: Silybum marianum (Dry)	350 mg
sodium ascorbate	112.5 mg
Equivalent: ascorbic acid	100 mg
Vitis vinifera seed Extract dry concentrate	1 mg
Equivalent: Vitis vinifera (Dry)	120 mg

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate
colloidal anhydrous silica
croscarmellose sodium
dl-alpha-tocopherol
hydrogenated soya oil
hydrolysed gelatin
hypromellose
magnesium stearate
maize starch
microcrystalline cellulose
povidone
silicon dioxide
sucrose

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary